Literature DB >> 10681364

A convenient assay for estimating the possible involvement of efflux of fluoroquinolones by Streptococcus pneumoniae and Staphylococcus aureus: evidence for diminished moxifloxacin, sparfloxacin, and trovafloxacin efflux.

R Beyer1, E Pestova, J J Millichap, V Stosor, G A Noskin, L R Peterson.   

Abstract

We developed a simplified assay for estimating efflux by measuring the effect of reserpine on the growth of Streptococcus pneumoniae and Staphylococcus aureus over 7 h. Reserpine enhanced ciprofloxacin and levofloxacin 17 to 68%. The hydrophobic drug trovafloxacin and the drug moxifloxacin, with a bulky C-7 substituent but hydrophilicity similar to that of levofloxacin, showed little (0 to 11%) reserpine-enhancing effect. The ease of resistant mutant strain selection correlated with efflux susceptibility.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10681364      PMCID： PMC89772          DOI： 10.1128/AAC.44.3.798-801.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Mechanism of action of sparfloxacin against and mechanism of resistance in gram-negative and gram-positive bacteria.

Authors:  L J Piddock; M Zhu
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

2.  A comparison of methods used for measuring the accumulation of quinolones by Enterobacteriaceae, Pseudomonas aeruginosa and Staphylococcus aureus.

Authors:  P G Mortimer; L J Piddock
Journal:  J Antimicrob Chemother       Date:  1991-11       Impact factor: 5.790

3.  Mutants of the Bacillus subtilis multidrug transporter Bmr with altered sensitivity to the antihypertensive alkaloid reserpine.

Authors:  M Ahmed; C M Borsch; A A Neyfakh; S Schuldiner
Journal:  J Biol Chem       Date:  1993-05-25       Impact factor: 5.157

4.  Destruction of low efficiency markers is a slow process occurring at a heteroduplex stage of transformation.

Authors:  N B Shoemaker; W R Guild
Journal:  Mol Gen Genet       Date:  1974

5.  Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.

Authors:  E Pestova; R Beyer; N P Cianciotto; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

6.  Quinolone resistance mediated by norA: physiologic characterization and relationship to flqB, a quinolone resistance locus on the Staphylococcus aureus chromosome.

Authors:  E Y Ng; M Trucksis; D C Hooper
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

7.  Fluoroquinolone resistance protein NorA of Staphylococcus aureus is a multidrug efflux transporter.

Authors:  A A Neyfakh; C M Borsch; G W Kaatz
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

8.  Mechanisms of fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  J Infect Dis       Date:  1991-05       Impact factor: 5.226

9.  Inducible NorA-mediated multidrug resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo
Journal:  Antimicrob Agents Chemother       Date:  1995-12       Impact factor: 5.191

10.  Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
View more
  27 in total

1.  In vitro development of resistance to six quinolones in Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus.

Authors:  M Boos; S Mayer; A Fischer; K Köhrer; S Scheuring; P Heisig; J Verhoef; A C Fluit; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 2.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

3.  Activities of newer fluoroquinolones against ciprofloxacin-resistant Streptococcus pneumoniae.

Authors:  E A Coyle; G W Kaatz; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

4.  Contributions of the 8-methoxy group of gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus pneumoniae.

Authors:  H Fukuda; R Kishii; M Takei; M Hosaka
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

6.  Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae.

Authors:  Estelle Marrer; Karen Schad; Andreas T Satoh; Malcolm G P Page; Maggie M Johnson; Laura J V Piddock
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

7.  Fluoroquinolone-resistant mutants of Burkholderia cepacia.

Authors:  C F Pope; S H Gillespie; J R Pratten; T D McHugh
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

8.  Fluoroquinolone-resistant Streptococcus pneumoniae strains occur frequently in elderly patients in Japan.

Authors:  Shin-Ichi Yokota; Kiyoshi Sato; Osamu Kuwahara; Satoshi Habadera; Naoyuki Tsukamoto; Hironori Ohuchi; Hirotsugu Akizawa; Tetsuo Himi; Nobuhiro Fujii
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

9.  Trends in antibiotic resistance in bacterial keratitis isolates from South India.

Authors:  Prajna Lalitha; Geetha Manoharan; Rajaram Karpagam; Namperumalsamy V Prajna; Muthiah Srinivasan; Jeena Mascarenhas; Manoranjan Das; Travis C Porco; Thomas M Lietman; Vicky Cevallos; Jeremy D Keenan
Journal:  Br J Ophthalmol       Date:  2016-04-29       Impact factor: 4.638

10.  Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA.

Authors:  Vijaya B Srinivasan; Govindan Rajamohan; Preeti Pancholi; Kurt Stevenson; Daniel Tadesse; Prapas Patchanee; Mario Marcon; Wondwossen A Gebreyes
Journal:  Ann Clin Microbiol Antimicrob       Date:  2009-06-17       Impact factor: 3.944
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.